87 related articles for article (PubMed ID: 15648949)
1. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
Gajewski TF
Curr Opin Investig Drugs; 2004 Dec; 5(12):1279-83. PubMed ID: 15648949
[TBL] [Abstract][Full Text] [Related]
2. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2326s-2330s. PubMed ID: 16609053
[TBL] [Abstract][Full Text] [Related]
3. [A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase].
Van den Eynde B
Bull Mem Acad R Med Belg; 2003; 158(7-9):356-63; discussion 364-5. PubMed ID: 15132006
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Muller AJ; DuHadaway JB; Donover PS; Sutanto-Ward E; Prendergast GC
Nat Med; 2005 Mar; 11(3):312-9. PubMed ID: 15711557
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
Poggi A; Zocchi MR
Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
7. Immune suppression in the tumor microenvironment.
Gajewski TF; Meng Y; Harlin H
J Immunother; 2006; 29(3):233-40. PubMed ID: 16699366
[TBL] [Abstract][Full Text] [Related]
8. Immune resistance orchestrated by the tumor microenvironment.
Gajewski TF; Meng Y; Blank C; Brown I; Kacha A; Kline J; Harlin H
Immunol Rev; 2006 Oct; 213():131-45. PubMed ID: 16972901
[TBL] [Abstract][Full Text] [Related]
9. Evading immunity: new enzyme implicated in cancer.
Garber K
J Natl Cancer Inst; 2012 Mar; 104(5):349-52. PubMed ID: 22349199
[No Abstract] [Full Text] [Related]
10. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment and immune escape.
Ferrone S; Whiteside TL
Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
[TBL] [Abstract][Full Text] [Related]
12. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
Zhang P; Su DM; Liang M; Fu J
Mol Immunol; 2008 Mar; 45(5):1470-6. PubMed ID: 17920123
[TBL] [Abstract][Full Text] [Related]
13. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies to improve tumor immunotherapy.
Begley J; Ribas A
Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
[TBL] [Abstract][Full Text] [Related]
15. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
17. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
Front Immunol; 2021; 12():789473. PubMed ID: 34938297
[No Abstract] [Full Text] [Related]
19. Escape from immune- and nonimmune-mediated tumor surveillance.
Malmberg KJ; Ljunggren HG
Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
[TBL] [Abstract][Full Text] [Related]
20. Restoring function in exhausted CD8 T cells during chronic viral infection.
Barber DL; Wherry EJ; Masopust D; Zhu B; Allison JP; Sharpe AH; Freeman GJ; Ahmed R
Nature; 2006 Feb; 439(7077):682-7. PubMed ID: 16382236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
